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Abstract
Background: DNA microarrays have become a nearly ubiquitous tool for the study of human disease, and
nowhere is this more true than in cancer. With hundreds of studies and thousands of expression profiles
representing the majority of human cancers completed and in public databases, the challenge has been effectively
accessing and using this wealth of data.
Description: To address this issue we have collected published human cancer gene expression datasets generated
on the Affymetrix GeneChip platform, and carefully annotated those studies with a focus on providing accurate
sample annotation. To facilitate comparison between datasets, we implemented a consistent data normalization
and transformation protocol and then applied stringent quality control procedures to flag low-quality assays.
Conclusion: The resulting resource, the GeneChip Oncology Database, is available through a publicly accessible
website that provides several query options and analytical tools through an intuitive interface.
Background
Although gene expression microarrays have been widely
used to study human disease, by far the most extensive
application has been to the analysis of human cancers.
D e s p i t et h el a r g en u m b e ro fa r r a ye x p e r i m e n t sd e p o s -
ited in public databases such as GEO [1] and ArrayEx-
press [2], our ability to perform meta-analyses of these
data to discover cross-cutting patterns has been ham-
pered by both the heterogeneous nature of the data and
the lack of consistent annotation of the experimental
samples. Although there have been some attempts to
organize these data in resources such as Oncomine [3]
and Genevestigator [4], both focus on analyses of sub-
sets of the data and neither fully addresses the problem
of integration across studies.
To overcome these limitations, we developed GCOD,
the GeneChip Oncology Database, a freely-available
web-accessible resource focused on gene expression pro-
files in cancer collected on the Affymetrix GeneChip
platform. Relative to other resources, GCOD has three
distinguishing features that we believe greatly enhance
its overall utility. First, since GCOD focuses on expres-
sion data derived from a single platform and on studies
where raw data are available, all datasets in GCOD are
uniformly processed and properly scaled such that levels
of gene expression in multiple samples across studies
are comparable. Second, quality control protocols have
been implemented in GCOD so that samples from
hybridizations of questionable quality are identified and
removed, improving the reliability of any subsequent
data analysis. Third, and most importantly, sample
annotations are manually curated based on descriptions
in the paper and provided in a tabular format that is
compatible with most microarray data analysis packages.
GCOD has a number if advantages over other data-
bases. First, the data have been reprocessed to provide
normalized and scaled values that can be compared
across studies. This is not possible at GEO as it is sim-
ply an access portal that has no online analysis tools.
Although ArrayExpress has several basic analysis tools,
the data are not consistently normalized, making global
analyses and their interpretation difficult. Oncomine
provides access to a variety of data types, but access is
limited for non-paying users so that certain data are not
available. Genevestigator is freely accessible to academic
users, but places access limitations on result sets and
analysis tool access for those who have not paid. Gene-
vestigator only includes data from GEO and not those
in ArrayExpress. In contrast, GCOD contains a more
comprehensive collection of cancer data, available with-
out restriction, and includes a set of basic analysis tools.
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Data processing
Raw data (CEL) files from experiments run on the Affy-
metrix GeneChip platform are identified based on the
keyword “cancer” and downloaded from public data-
bases. These were first processed using the MAS5.0
algorithm (mas5) implemented in the Bioconductor
package ‘affy’ to get detection calls and the 3’ to 5’ signal
ratios for the GAPDH and b-ACTIN probesets. All the
CEL files were then normalized using RMA [5,6] (rma
in the affy package) for each experimental group (study).
After RMA normalization, expression values are scaled
such that the mean of each experiment is set equal to a
common value.
For each GeneChip platform, probset definitions and
other annotation are obtained from CDF (chip descrip-
tion files) files, supplied by Affymetrix,
Sample information accompanying source data files
are parsed and manually curated using information in
the accompanying publication to classify samples based
on experimental factors including primary tissue source,
cancer status (cancer or normal), primary tumor or
metastasis, and treatment. Processed data along with
detailed sample information were loaded into our
GCOD relational database. A summary of all datasets
available is listed in Table 1 (cancer types and number
of hybridizations), and details about each study are
listed in Additional File 1 (the entire list of studies;
GEO or AE accession; PubMed references; number of
samples); this is also available from the GCOD website
(http://compbio.dfci.harvard.edu/gcod).
Database implementation
The GCOD database is implemented in an Oracle data-
base system that consists of 3 separate database servers
and an Apache web server that hosts the GCOD web
site (Figure 1).
Database Implementation
After curation and normalization, data are loaded into
an ETL (extract, transform and load) database via a ser-
ies of Perl scripts designed specifically for the formats
produced during curation. The ETL database is used for
loading and cleaning the data prior to transfer to a QA/
QC database; the schema for the ETL database is nor-
malized to 3rd normal form. Oracle sqlldr is used to
bulk-load gene expression data from the flat-files written
by the Perl scripts into target database tables. These
data are marked with a ‘data set’ identifier (dba_id), so
that the results of an analysis can be rapidly accessed.
Once the data for a study are completely loaded and
checked, they are transferred from the ETL database to
our QA/QC database by SQL insert statements issued
on an Oracle database link. The QA/QC database is the
data source for our internal web site, which we use to
evaluate the presentation and completeness of the data
in the web pages generated by our Apache server. After
inspection, the data are transferred to the production
GCOD database by SQL insert statements issued on an
Oracle database link.
Data Model
The production GCOD database is maintained in an
Oracle 11 g database server, which includes multiple
schemas, in addition to the GCOD schema (Figure 2).
The schema for this database follows a “star” schema,
dimensional database model, in which measurement
data (such as expression data values) are stored in a
“fact” table, and categorical data are stored in “dimen-
sion” tables. The dimensions represent items that
include studies, experimental factors, probesets, sample
materials, array designs, hybridizations, and data sets.
The main fact table, dbadata, is partitioned into 3 sepa-
rate tablespaces based on the analysis algorithm used to
generate the data (either MAS5, RMA or RMA + scaling)
Table 1 Number of Arrays in GCOD Grouped by
Cancer Type
Cancer Type Number of Arrays
adrenal cancer 50
bladder cancer 234
brain cancer 818
breast cancer 2789
cancer cell lines 950
cervical cancer 33
colon cancer 73
endometrium 18
esophagus cancer 24
germ cell cancer 214
head and neck cancer 197
kidney cancer 40
leukemia 1760
lung cancer 560
lymphoma 358
multicancer 511
multiple myeloma 192
nci60 478
normal tissue 120
ovarian cancer 277
pancreas cancer 78
prostate cancer 952
renal cancer 34
sarcoma 60
thyroid cancer 96
Unassigned 2681
Total 13597
Counts of the numbers of arrays stored in the GCOD as a function of assigned
cancer type.
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Page 2 of 10and indexed on those foreign keys most commonly used
in our queries. This produces exceptionally fast retrieval
times. The dimension tables are not partitioned. The
GCOD web site relies on information provided by the
Gene Index (TGI) Resourcerer database which also
resides in the production database server. The TGI data-
base supplies GenBank accessions, PubMed identifiers
and pre-computed mappings between various Affymetrix
chips.
Web site implementation
The GCOD website is implemented on an Apache web
server through a series of Perl/CGI/DBI scripts. These
scripts use the CGI interface to present web pages, and
the DBI interface to access and query the production
GCOD database. The Perl/CGI/DBI scripts also access
Resourcerer to obtain pre-computed mappings between
Genbank, Ref_seq, probeset and array-type identifiers.
This allows us to map probesets on one Affymetrix chip
to probesets on another Affymetrix chip (whether they
are identical or not). Analysis of GCOD data that is pre-
sented on the website is performed in R by direct sys-
tem calls.
Utility and Discussion
Although the database provides overall organization of the
information we have compiled, the most important aspect
of GCOD is its presentation of those data to the end-
users. We developed a series of web-based tools to allow
access to the data based on use cases representing com-
mon questions users ask of expression data (Figure 3A).
Study-centered views allow users to browse the individual
studies, check the quality of hybridizations, download the
processed data, and perform preliminary data analysis
online. Gene-centered views allow users to query the
expression profiles across multiple datasets. The integra-
tion of the TGI Resourcerer database [7] provides up-to-
date annotation of the array probes and facilitates cross-
comparison between the various Affymetrix array
platforms.
Study-centered views
The study-centered views allow users to browse the list
of published studies and to search for datasets of inter-
est. For each individual study the title of the publica-
tion, a summary of samples and experimental factors
involved, and the total number of hybridizations on the
specified array type are displayed. Listed next to each
study name are three separate options: access QC infor-
mation, compare experimental groups using a t-test,
and download the dataset. The QC information (Figure
3B) includes two scatter plots showing the quality con-
trol information derived from the MAS 5.0 algorithm;
one is the percentage of ‘Present’ calls vs. scaling factor
(target = 500) and the other is the 3’ to 5’ signal ratios
of the control transcripts GAPDH versus b-ACTIN [8];
both plots identify questionable hybridizations as out-
liers in the graphs.
To provide basic utilities for comparison between
phenotypic groups defined by the curated sample anno-
tation, we implemented Student’s t-test with data-
trimming filters, p-value thresholds for significance, and
Bonferroni correction for multiple testing. Results are
presented in a table that lists significant genes together
with group means, standards deviations, differences
between the means, degree of freedom and raw (and
corrected) p-values. The results are sorted by p-value
a n de a c hp r o b e s e tn a m ei sl i n k e dt oe x p r e s s i o nv a l u e s
for all the samples in our database. Users can browse
the results and download them as a text file.
The download function offers users options to choose
either MAS 5.0 or RMA normalized data, whether or
not to exclude the data points from questionable hybri-
dizations flagged by the QC filter, and whether the data
should be trimmed by removal of data (rows) with less
than the specified percentage of MAS 5.0 ‘Present’ calls
across samples (columns). Sample annotations classified
by experimental factors will be listed on the header sec-
tion of the downloaded data table with an option to
arrange the columns by any user-chosen experimental
factor. In addition, RMA normalized expression data, in
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Figure 1 Schematic representation of the GCOD databases.
Publicly available gene expression data are downloaded from
ArrayExpress or GEO. These CEL and sample annotation files are
reprocessed and saved as flat files; the MAS5 normalized, RMA
normalized, scaled-RMA expression data, and curated sample
annotation data are loaded into an ETL database having a schema
in 3
rd normal form. There the data are further curated, and then
transferred to a QA/QC database having a warehouse schema. In
the QA/QC database the data are viewed on our internal web site
to assess completeness. The data are then transferred to our GCOD
database schema, which is accessed by the GCOD web application.
Translation of GenBank and probeset identifiers is done by querying
the TGI Resourcerer databases.
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Page 3 of 10Figure 2 GCOD Database Schema. The schema for the GCOD database consists of 12 tables in a “star” layout. The main ‘fact’ table, dbadata, is
split into 3 tablespaces that are distinguished by the algorithm used to generate the data, either MAS5, RMA, or scaled RMA, resp. The remaining
tables are ‘dimension’ tables that contain characteristic and attribute information about the objects in the database. Lines and arrows indicate
the relationships between tables and the key field linking the tables together.
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Page 4 of 10the format of the BioConductor eSet data object, can be
downloaded with the “R Data Download” link.
Gene-centered views
A common GCOD use case involves comparing the
expression of a single gene across a large number of sam-
ples. Gene-centric searches allow users to query the data-
base using any of the following gene-specific identifiers
including gene symbol, a range of gene names and syno-
nyms, GenBank accession number, UniGene id, RefSeq
accession, Affymetrix probeset id, LocusLink identifier
(equivalent to the Entrez Gene ID), or free text descrip-
tion. Lists of up to 300 identifiers may also be provided
for batch searches (examples of entries for each identifier
are shown in Table 2). These identifiers are automatically
mapped to probeset ids, which are the primary identifiers
used for expression measures. Graphical displays of
Ratio 5' to 3' Signal
0
200
400
600
800
1000
1200
0 20 40 60 80 100 120 140 160 180 200
GAPDH ratio
A
c
t
i
n
 
r
a
t
i
o
Hybridization QC
0
50
100
150
200
250
300
350
0 1 02 03 04 05 06 07 08 0
Percentage of MAS5 "Present" Calls
S
c
a
l
e
 
F
a
c
t
o
r
 
(
t
o
 
5
0
0
 
f
o
r
 
M
A
S
5
)
AB
CD
Figure 3 GCOD Screenshots and QC Analysis. A. The GCOD web site main page. B. A representative view of the QC information available on the
GCOD site. C. Assessment of MAS5 Present/Absent call and scaling factor data. D. Display of the GAPDH and b-ACTIN 5’ to 3’ probe signal ratios.
Table 2 Example Gene Identifier Entries for Gene-Centric
Searches
Identifier Example List
Probeset 33218_at 33218_at, 1802_s_at, 216836_s_at,
210930_s_at
Genbank# NM_006468 NM_006468NM_004452
Locus Link/
Entrez ID
2103 2103, 2064
Gene Symbol ESRRB ESRRB ERBB2 HER-2
UniGene ID Hs.446352 Hs.446352, ERBB2, HER2, 33218_at
Ref_seq ID NM_006468 NM_006468 NM_004452
Free text tumor tumor, estrogen receptor
Single entries may be entered as shown below. Lists may be entered as
comma, space, tab or newline separated identifiers. Any of the listed identifier
types can be used in combinations in a list.
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Page 5 of 10expression values across all samples are presented as box
plots which depict normalized expression results on a
study-by-study basis (Figure 4). Box plots showing con-
trasting expression between the primary experimental
subgroups (described in the corresponding published
manuscript) can be generated as well (figure 5).
As an example, we examined VEGF expression across
all of the studies represented in GCOD. Figure 4 shows
the expression of all four probesets on the HG-U133A
array that are annotated as VEGF probes. For most can-
cers, there is little difference in expression for VEGF;
however the renal cancer studies clearly show differen-
tial expression for VEGF (Figure 4). One can also look
at individual probesets. Figure 5 shows the individual
mean normalized expression values of probeset
212717_x_at (VEGF) as box plots for each sample
grouping from the Copland kidney cancer study [9]
(Figure 5). The normalized data values used in generat-
ing the box plots can be downloaded in each case.
The expression of VEGF appears decreased compared
to normal kidney samples in the Corbin, et al. [10]
study of Wilms’ tumor. We believe these observations
to be completely accurate based on published experi-
mental work that describes decreased VEGF expression
in Wilms’ tumor [11] using RT-PCR. Compared to
clear-cell renal cell carcinoma (ccRCC) (Lenburg et al.
[12]), which is a highly vascularized tumor [13], Wilms’
tumor is an early childhood nephroblastoma that is
non-invasive; elevated VEGF would be expected in
ccRCC, but not necessarily so in Wilms’ tumor. The
published data appear to support our expression-based
observations that VEGF has elevated expression in
ccRCC renal cancer.
In order to evaluate what other genes have altered
expression in kidney cancer, we viewed the GCOD data
‘by study’ and selected one of the kidney cancer studies
(Lenburg, et al. [12]). The top 20 entries from a t-test con-
trasting tumor versus normal samples (Table 3) from the
Lenburg kidney cancer study shows several probesets
other than VEGF that appear to have significant differ-
ences in their expression data. (The expression of VEGF is
listed in these results, but is item 271 in the t-test result
210512_s_at 210513_s_at
211527_x_at 212171_x_at
Figure 4 Expression of VEGF in Kidney cancer. Data from the expression as reported by probesets 210512_s_at (A), 210513_s_at (B),
211571_x_at (C), and 212171_x_at (D) in two studies of kidney cancer (9, 12). These reporters of VEGF gene expression show distinct gene
expression differences in tumor vs. normal sample groups (top to bottom): clear cell carcinoma (Lenburg et al.), normal renal tissue (Lenburg et
al.), stage 2 renal tumor (Copland, et al.), stage 1 renal tumor (Copland, et al.), normal renal epithelium (Copland, et al.).
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Page 6 of 10list.) We chose two for further examination. The expres-
sion of Calbindin1 (CALB1) and 4-Hydroxyphenylpyru-
vate dioxygenase (HPPD) are shown in Figure 6. Both
genes are differentially repressed in these kidney cancer
studies; their expression is opposite that of VEGF.
Calbindin-D28k, CALB1, is a vitamin D dependent,
calcium binding protein that is expressed in several tis-
sues including the kidney, pancreas and brain [14].
CALB1 acts to buffer calcium concentration in the
blood and tissues, and may have regulatory properties
similar to other calcium binding proteins, e.g. calmo-
dulin and troponin-C. HPPD is part of the tyrosine
catabolic pathway; it converts 4-hydroxyphenylpyruvate
to homogentistate which is subsequently catabolyzed
to acetoacetate and fumarate. HPPD is expressed in
the liver and kidneys, as well as cerebral cortex, cere-
bellum and hippocampus. Mutations in HPPD result in
type III tyrosinemia, a hereditary condition in which
mild mental retardation and seizures occur due to the
accumulation of tyrosine and phenylalanine in the
blood. Oddly enough, inactivation of or deletion of
HPPD alleviates the effects of type I tyrosinemia
caused by deficiency of fumarylacetoacetase (the last
enzyme in the tyrosine catabolism pathway), and an
accumulation of fumarylacetoacetate, succinylacetoace-
tate and derivatives [15,16].
Data Assessment
The current release of GCOD includes 125 studies con-
sisting of a total of 13,591 hybridizations with data col-
lected on 15 different Affymetrix GeneChip types as
summarized in Table 4. The studies have an average of
4 experimental factors per study, and a modal value of 2
(±2.00, based on a Poisson distribution) and a maximum
number of 30 experimental factors (lymphoma_hum-
mel). Twenty-eight studies have only a single experi-
mental factor. There are 198 different experimental
factors assigned to the 125 studies in GCOD; the experi-
mental factor “disease_state” is used most often, in 110
studies.
212171_x_at
Figure 5 Expression data from Probeset 212171_x_at. RMA normalized and scaled signal data for probeset 212171_x_at in kidney tumor vs.
normal tissue samples from Copland et al. (9). Box and whisker plots are overlaid with individual data points from the sample groups listed in
the legend for Figure 4.
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Page 7 of 10Table 3 Results from t-test contrasting normal versus tumor samples from the Lenburg renal cancer study
probeset gene name gene symbol Adjusted p-value
205626_s_at calbindin 1, 28kDa CALB1 2.41E-08
216910_at 2.46E-08
206054_at kininogen 1 KNG1 2.60E-08
219188_s_at LRP16 protein LRP16 2.64E-08
206024_at 4-hydroxyphenylpyruvate dioxygenase HPD 6.79E-08
205243_at solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 SLC13A3 7.28E-08
221298_s_at solute carrier family 22 (organic anion transporter), member 8 SLC22A8 9.68E-08
221605_s_at pipecolic acid oxidase PIPOX 9.72E-08
206716_at uromodulin (uromucoid, Tamm-Horsfall glycoprotein) UMOD 9.74E-08
205625_s_at calbindin 1, 28kDa CALB1 1.20E-07
204704_s_at 1.21E-07
209443_at serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 SERPINA5 1.47E-07
206457_s_at deiodinase, iodothyronine, type I DIO1 1.61E-07
221590_s_at aldehyde dehydrogenase 6 family, member A1 ALDH6A1 2.05E-07
206484_s_at X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound XPNPEP2 2.19E-07
216092_s_at solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 SLC7A8 3.27E-07
202752_x_at solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 SLC7A8 3.75E-07
204254_s_at vitamin D (1,25- dihydroxyvitamin D3) receptor VDR 4.62E-07
205983_at cyclin-dependent kinase (CDC2-like) 10 CDK10 5.10E-07
218844_at hypothetical protein FLJ20920 FLJ20920 5.65E-07
[...]
210512_s_at vascular endothelial growth factor VEGF 7.22E-03
The kidney_lenburg study was selected from GCOD. Then t-test was performed with the 2 sample groups; low-quality hybridizations and hybridizations with less
than 5% Present calls were excluded from the t-test. Also, the Bonferonni correction for multiple testing was applied. Only the top 20 results are shown from a
list of 308 results returned. Item 271 (VEGF) also is listed.
Calbindin1
205626_s_at
A
4-Hydroxyphenylpyruvate 
Dioxygenase (4HPD)
206024_at
B
Figure 6 Expression of CALB1 and 4-HPPD in Kidney cancer. RMA normalized and scaled signal data for probesets 205626_s_at (CALB1) and
206024_at (4-HPPD) in two studies of kidney cancer (9, 12). The sample groups are listed in the legend for Figure 4.
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Page 8 of 10QC filters identify potentially poor hybridizations
(Figures 3C and 3D) based on criteria that include: a)
scaling factor values greater than 100, b) actin_ratio
greater than 10 and gapdh_ratio greater than 10, and
c) present call (detection) percentage less than 10.
Hybridizations failing to meet these criteria are
f l a g g e df o re x c l u s i o n ,b u to n l ye x c l u d e di ft h eu s e r
selects the option to do so. Hybridizations failing to
meet those criteria represent a) 0.124%, b) 3.70% and
c) 1.94% of the data, respectively, with 5.63% of the
hybridizations, in total, that fail to meet one or more
of these criteria.
Conclusion
The GCOD web site provides access to normalized and
scaled gene expression data from analyses of a variety of
cancer types. The site provides filtering based on QC
analysis of the data, and the ability to do t-tests based
on the experimental parameters for the individual stu-
dies in the database. The GCOD site also offers the
option to download data for each study. In the near
future we plan to augment the GCOD web site to
include: a) additional data QC metrics, b) a cancer gene
signatures search function, and c) a batch search func-
tion. Lastly, new data sets are added to GCOD as they
become available.
Availability
The data in GCOD is freely accessible at http://comp-
bio.dfci.harvard.edu/gcod.
Supplementary information: supplementary data are
available at http://compbio.dfci.harvard.edu/gcod.
Additional material
Additional file 1: List of Data Sets Contained in the GCOD.
Characteristics of the data sets available in GCOD. The study name is a
concatenation of the tumor type and the publication first author’s name.
Some studies have no available PubMed ID. Note: several studies include
multiple ArrayDesign types and occupy more than one row in the table
below.
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